It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Sygnature Discovery delivers advanced biotransformation solutions that help you optimize compounds and make confident decisions faster. Our scientists combine deep expertise with cutting-edge analytical platforms to provide high-resolution data that drives success from hit identification through preclinical candidate selection.
Understanding a compound’s biotransformation is essential for predicting its metabolic fate, stability, and potential liabilities.
Using high-resolution LC-MS/MS, we deliver detailed metabolite profiling to identify primary and secondary pathways, reactive intermediates, and species-specific differences. These insights inform structure optimization, support safety assessments, and guide strategic decisions throughout drug discovery.
Biotransformation – Structural Elucidation
Metabolite identification and structural elucidation are critical for characterization of biotransformation pathways and impurity profiles. We use in vitro systems such as cryopreserved primary hepatocytes and liver microsomes, we simulate human metabolism to identify and profile drug metabolites. These profiles are then compared across preclinical species to assess metabolic translatability and support species selection for toxicology studies.
Our Approach
Our approach combines high-resolution accurate-mass spectrometry (HRMS) with photodiode array (PDA) detection for sensitive and selective detection of major and minor metabolites. By integrating targeted analyses with data-independent acquisition (DIA) strategies, we uncover metabolic liabilities, elucidate degradation products and impurities, and ensure precise mass determination and elemental composition. This comprehensive profiling informs medicinal chemistry determination, supports safety evaluations, and strengthens regulatory submissions.
Why Choose Sygnature Discovery for Biotransformation Support?
Our MetID team delivers tailored studies using high-resolution mass spectrometry to achieve precise detection and structural elucidation. We analyze a wide range of matrices, including in vitro systems (cryopreserved primary hepatocytes, liver microsomes, plasma, whole blood) and in vivo samples from human and animal studies- covering urine, feces, plasma, bile, and blood. This tailored approach ensures scientifically rigorous insights aligned with your project’s objectives.
Sygnature Discovery is attending SLAS2026 in Boston. Meet our Bioscience, DMPK and Physical Sciences experts as they share practical insight across early discovery and lead pre‑clinical drug discovery workshops onsite.
Sygnature Discovery, in collaboration with Iktos, presents a poster outlining the…
Posters
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
